Licensing & Technology Transactions
![](https://www.mintz.com/sites/default/files/styles/card/public/media/images/2020-11-23/Case_Study-ImmunoGen_Secures_Partial_Sale-Mintz.jpg?itok=Va1oTj95)
Mintz represented ImmunoGen in a $200 million non-dilutive royalty transaction of its interest in Kadcyla with funds managed by TPG Special Situation Partners.
![](https://www.mintz.com/sites/default/files/styles/card/public/media/images/2020-11-23/Case-Study-Intarcia_Secures_Novel_Financing.jpg?itok=IHrELK5U)
In the first transaction of its kind, Mintz represented Intarcia Therapeutics in two synthetic royalty financings with an equity conversion option valued at $5.5B for ITCA 650.
![](https://www.mintz.com/sites/default/files/styles/card/public/media/images/2020-10-07/Case-Study-ARIAD_Royalty_Monetization-Mintz.jpg?itok=4XAbrMvt)
Mintz represented ARIAD Pharmaceuticals in a synthetic royalty financing in which PDL BioPharma agreed to provide up to $200 million in revenue interest financing to ARIAD in exchange for royalties on worldwide net revenues of Iclusig (ponatinib).
![](https://www.mintz.com/sites/default/files/styles/card/public/media/images/2020-07-22/Case_Study-MGH-Entyvio-Mintz.jpg?itok=uV6JBozA)
Mintz represented Massachusetts General Hospital and Partners HealthCare in a deal that enables them to monetize part of their royalty interests in Entyvio, an antibody used to treat digestive diseases, to invest in research. Royalty Pharma paid $94 million in the true sale roll-up transaction.
![](https://www.mintz.com/sites/default/files/styles/card/public/media/images/2019-01-11/Case-Study_Hero_Spero_Therapeutics_Mintz.jpg?itok=LaAtmv2i)
Mintz advised biopharma company Spero Therapeutics on an agreement with Everest Medicines regarding the development and commercialization of a product to treat multidrug-resistant bacterial infections and option to license another.
![](https://www.mintz.com/sites/default/files/styles/card/public/media/images/2018-10-04/Case-Study_Hero_Biotech-transaction-concerning-drug-candidate_Mintz.jpg?itok=VN-x7xTQ)
Mintz represented ImmunoGen, a maker of targeted anticancer therapeutics, in a transaction that netted $194 million. The deal provided ImmunoGen with cash and liquid assets in exchange for assigning certain royalty revenues for the breast cancer treatment Kadcyla to TPG Special Situations Partners.
![](https://www.mintz.com/sites/default/files/styles/card/public/media/images/2021-08-03/Case_Study-Hero-Major_Financial_Services_Company-Mintz-small_0.jpg?itok=SfX72Wux)
Mintz attorneys negotiated a termination agreement with a large Indian technology vendor that had failed to meet the terms of its contract. The successful negotiation eased the client's transition to a new vendor while preserving the client's right to enforce claims against the old provider.
![](https://www.mintz.com/sites/default/files/styles/card/public/media/images/2018-07-19/Case-Study_Hero_Major-Academic-Medical-Center_Mintz.jpg?itok=LRjxkXDq)
Mintz attorneys served as lead lawyers in the negotiation of a transaction for the procurement of a software as a service (SaaS) care management platform. The resulting arrangement greatly bolstered our client's bottom line.
![](https://www.mintz.com/sites/default/files/styles/card/public/media/images/2021-08-03/Case-Study_Hero_Major-Multinational-Mutual-Fund-and-Financial-Services-Company_Mintz-small.jpg?itok=MGbJStv6)
Mintz served as lead counsel to a major multinational mutual fund and financial services company in a multiyear initiative to purchase cloud computing services that will be used across the client's global enterprise.
![](https://www.mintz.com/sites/default/files/styles/card/public/media/images/2018-04-17/Case-Study_Hero_InhibRxs_Prescription_to_Success_Mintz.jpg?itok=cEdWwSeB)
Mintz has represented oncology-focused biotherapeutic company Inhibrx LP since its inception. Mintz attorneys have advised Inhibrx on licensing deals and financing deals involving unusual corporate and tax structuring and international aspects.
![](https://www.mintz.com/sites/default/files/styles/card/public/media/images/2018-05-08/Case-Study_Hero_Representing_BeiGene_in_Strategic_Collaborations_Mintz.jpg?itok=Uh8bF-Cd)
Mintz represented BeiGene, Ltd. in its global strategic collaboration with Celgene Corporation to develop and commercialize BeiGene’s cell death protein 1 (PD-1) inhibitor tislelizumab (BGB-A317) for patients with solid tumor cancers. Mintz also assists BeiGene with licensing transactions.